Actionable news
All posts from Actionable news
Actionable news in MCRB: Seres Therapeutics Inc,

Seres Plunges on Microbiome Drug Fail, Execs Profit on Insider Sales

Microbiome drug developer Seres Therapeutics (MCRB) plummeted Friday after its lead drug failed to reduce the incidence of Clostridium difficile infection in a mid-stage study.

The negative study results from Seres is a setback for companies trying to harness the power of bacteria to treat diseases. Clostridium difficile, or c. diff, can cause life-threatening diarrhea and is an acute health risk for patients in hospitals.

Seres shares opened Friday trading down 76% to $8.52.

Seres' CEO Roger Pomerantz...